Market Place
Sourcing Support
All News #Library
Others
AOP Health US Launches First Rapiblyk Treatment in US
28 Apr 2026 //
FIRSTWORD PHARMA
FDA Approves RAPIBLYK for Pediatric SVT Treatment
15 Apr 2026 //
BUSINESSWIRE
AOP Health Adopts Veeva Industry Cloud For Life Sciences
10 Mar 2026 //
PR NEWSWIRE
AOP Health US, Secures Pharma Deal With Premier Inc
10 Feb 2026 //
BUSINESSWIRE
AOP Health`s Rapiblyk Now Accessible via Vizient Contract
05 Feb 2026 //
BUSINESSWIRE
AOP Health`s Rapiblyk Available Through Top US Healthcare Firms
12 Jan 2026 //
GLOBENEWSWIRE
US FDA Approves RapiblykTM for Atrial Fibrillation and Flutter
27 Nov 2024 //
BUSINESSWIRE
AOP Health`s Clinical Program Delivers New Hematology/Oncology Results
10 Jun 2024 //
BUSINESSWIRE
AOP Health Announces Findings in Patients With Polycythemia Vera to Be Presented
07 Dec 2023 //
BUSINESSWIRE
AOP Health: Completed Study Strengthens Development for ropeginterferon alpha 2b
01 Jun 2023 //
BUSINESSWIRE
AOP Health presents latest updates on BESREMi in Polycythaemia Vera at ASH
13 Dec 2022 //
BUSINESSWIRE
AOP Health Starts Research for Leukemia Treatment
01 Aug 2022 //
GLOBENEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.